Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Centessa Pharmaceuticals (CNTA) over the last 1 years, with Sep 2025 value amounting to $125,000.

  • Centessa Pharmaceuticals' Gains from Investment Securities fell 87.11% to $125,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $125,000, marking a year-over-year decrease of 99.06%. This contributed to the annual value of $9.7 million for FY2023, which is 4814.08% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Gains from Investment Securities of $125,000 as of Q3 2025, which was up 103.35% from -$3.7 million recorded in Q4 2024.
  • Over the past 5 years, Centessa Pharmaceuticals' Gains from Investment Securities peaked at $9.7 million during Q1 2023, and registered a low of -$3.7 million during Q4 2024.
  • In the last 3 years, Centessa Pharmaceuticals' Gains from Investment Securities had a median value of $970,000 in 2024 and averaged $2.0 million.
  • Data for Centessa Pharmaceuticals' Gains from Investment Securities shows a maximum YoY crashed of 87.11% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Gains from Investment Securities stood at -$206,000 in 2022, then reached $9.7 million in 2023, then reached -$3.7 million in 2024, then plummeted by 87.11% to $125,000 in 2025.
  • Its last three reported values are $125,000 in Q3 2025, -$3.7 million for Q4 2024, and $970,000 during Q3 2024.